Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 1 3Phase EARLY_PHASE1 1Phase 3 1

Status

Terminated 2Completed 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Genitourinary 2Gastrointestinal 2Dermatologic 2Thoracic 1Sarcoma 1Plasma cell 1Myeloid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Intraocular Lymphoma 1Burkitt Lymphoma 1

Interventions

Rituximab 689Cyclophosphamide 615Vincristine 285Etoposide 272Doxorubicin 271Cytarabine 230Prednisone 229Methotrexate 221fludarabine phosphate 189Filgrastim 187Dexamethasone 180fludarabine 176Lenalidomide 165Radiotherapy 128Melphalan 127Peripheral Blood Stem Cell Transplantation 123Busulfan 118Bendamustine Hydrochloride 116Granulocyte Colony-Stimulating Factor 113Bortezomib 112ibrutinib 111Mycophenolic Acid 110venetoclax 106Whole-Body Irradiation 106obinutuzumab 105Tacrolimus 105Gemcitabine 92zanubrutinib 81Specimen Handling 80Cyclosporine 76

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × oblimersen × Lymphoid × Clear all
NCT00054639 2014-05-28

Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
48 enrolled 5 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

NCT00080847 2013-01-07

S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
160 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT00301795 2013-01-07

Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
52 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡